Truist Financial
VRCA icon

Truist Financial’s Verrica Pharmaceuticals VRCA Stock Holding History

Truist Financial’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,055
Closed -$15.3K – 2635
2024
Q3 		$15.3K Hold
1,055
– – ﹤0.01% 2479
2024
Q2 		$76.9K Hold
1,055
– – ﹤0.01% 2594
2024
Q1 		$62.4K Hold
1,055
– – ﹤0.01% 2574
2023
Q4 		$77.2K Sell
1,055
-538
-34% -$22.1K ﹤0.01% 2583
2023
Q3 		$61.9K Hold
1,593
– – ﹤0.01% 2545
2023
Q2 		$91.9K Buy
1,593
+463
+41% +$28.1K ﹤0.01% 2520
2023
Q1 		$73.4K Hold
1,130
– – ﹤0.01% 2523
2022
Q4 		$31.1K Hold
1,130
– – ﹤0.01% 2529
2022
Q3 		$33K Hold
1,130
– – ﹤0.01% 2481
2022
Q2 		$21K Hold
1,130
– – ﹤0.01% 2603
2022
Q1 		$92K Buy
+1,130
New +$93.1K ﹤0.01% 2617

Other funds holding VRCA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Truist Financial's VRCA Position: Q4 2024 in Review

Truist Financial sold out of Verrica Pharmaceuticals (VRCA) in Q4 2024, closing a stake of 1,055 shares — an estimated $15.3K sold.

Truist Financial first reported a position in VRCA in Q1 2022 and held it in 11 quarters. The position peaked at $92K in Q1 2022. 81 funds tracked by Wall St. Rank hold VRCA as of Q4 2024.

  • Truist Financial reported no remaining Verrica Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Truist Financial sold 1,055 Verrica Pharmaceuticals shares in Q4 2024, an estimated $15.3K.
  • Truist Financial first reported a position in Verrica Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Truist Financial's Verrica Pharmaceuticals position peaked at $92K in Q1 2022.
  • 81 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2024.

Based on Truist Financial's 13F filing for Q4 2024, filed 31 Jan 2025.